Denali Posts First AVLAYAH Sales as Pipeline Setbacks Mount
Denali Therapeutics logged $3.6 million in first-quarter AVLAYAH sales while absorbing a Biogen Parkinson's failure and a Takeda contract termination.
Denali Therapeutics (DNLI) reported $3.6 million in net product revenue from AVLAYAH in the drug's first full quarter of commercial availability, the biotechnology company's initial financial payoff from a pipeline that has otherwise delivered a string of setbacks this year.
The revenue arrived three months after AVLAYAH's March 2026 approval by the Food and Drug Administration, following a first quarter in which the drug generated no meaningful sales. Denali guided third-quarter AVLAYAH revenue to $10.0 million to $12.0 million, implying roughly a tripling of sales from the second quarter. The launch also left its mark on the balance sheet for the first time, with $3.9 million in accounts receivable, $4.1 million in inventory, and a $35.3 million net intangible asset tied to the drug's developed technology, all of which stood at zero at the end of 2025.
That commercial launch also introduced a new liability: a $205.2 million obligation tied to a revenue participation right agreement, a financing structure now reflected on the balance sheet alongside the product-related assets.
Research and development spending fell to $97.0 million in the second quarter from $102.7 million a year earlier, a decline the company attributed to lower small-molecule program costs and reduced clinical spending on tividenofusp alfa. Selling, general and administrative expenses moved the other direction, rising to $36.3 million from $32.3 million as Denali added headcount to support the AVLAYAH launch. With total operating expenses roughly flat at $134.1 million versus $135.0 million a year earlier, the net loss widened modestly to $127.6 million from $124.1 million, driven by a drop in interest and other income to $3.0 million from $10.8 million.
Denali's pipeline saw two of its more advanced programs unravel during the quarter. The Phase 2b LUMA study of DNL151/BIIB122 in idiopathic Parkinson's disease, developed with Biogen, failed to meet its primary or secondary endpoints, and the two companies discontinued the program in that indication in May 2026, narrowing it to the smaller Phase 2a BEACON study in genetically confirmed LRRK2 carriers. Separately, Takeda terminated its co-development and co-commercialization agreement for DNL593 in April 2026, a disclosure that had not appeared in either the Q1 2026 or June 2026 releases. Denali also pushed back its data timeline for DNL593 in frontotemporal dementia with progranulin mutations, now expecting results in 2027 rather than by the end of 2026, to allow a longer observation window for a neurofilament light biomarker.
Against those setbacks, Denali advanced newer programs. Two Alzheimer's disease candidates, DNL628 and DNL921, moved into clinical development during the quarter, with DNL921 entering a Phase 1/1b study, and DNL952 for Pompe disease reached first patient dosing, with initial data expected in 2027.
Cash, cash equivalents and marketable securities totaled approximately $940.0 million as of June 30, 2026, down from $966.2 million at the end of 2025. That balance rose to more than $1.1 billion on a pro forma basis after Denali closed the sale of a Priority Review Voucher for $195 million in July 2026, converting an agreement signed on June 18, 2026 into realized cash.